Precision BioSearch Co-founder, Malcolm Silander, will deliver a half-day seminar to 14 Founders of the UK’s most exciting early-stage biotech companies as part of the Pioneer Group Launch Accelerator programme.
Precision BioSearch was delighted to partner with Myricx Bio, a biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), to secure the appointment of Dr Francesca Zammarchi as Chief Scientific Officer.
Biotech investment has taken a considerable downward turn over the past 18 months, impacted by the global macroeconomic situation and a return to lower levels of funding post-pandemic.
Precision BioSearch partnered with SENISCA, an award-winning biotechnology company developing RNA based therapeutics to reverse cellular senescence and target age-related disease
Our Co-founder, Malcolm Silander, chaired the discussion which formed the basis of Andrew McConaghie’s (In Vivo / Citeline) recent article, ‘How to be an early-stage Biotech CEO in challenging times’.
Precision BioSearch is delighted to announce our corporate sponsorship of Bio Equity Europe 2023, being held from May 14-16th in Dublin, Ireland.
Precision BioSearch was pleased to partner with NRG Therapeutics, an innovative neuroscience company targeting mitochondrial dysfunction, to secure Gilles Ouvry as VP Chemistry and Vad Lazari as VP Biology.
After several record years for biotech investment, the market has taken a downward turn in the past year.
Precision BioSearch partnered with Dark Blue Therapeutics, a biotech company developing a pipeline of oncology programs from the University of Oxford and therapeutics accelerator LAB282.
Precision BioSearch is delighted to congratulate Tom Coulter on his appointment as Head, Drug Discovery Programs and Partnerships with Dalriada Drug Discovery.